Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Condition: Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Gastric Cancer; Squamous Cell Carcinoma of the Head and Neck; Bone Cancer; Advanced Cancer; Recurrent Disease; Metastatic Tumours
MeSH terms: Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis; Bone Neoplasms
Intervention: 177Lu-3BP-227 (also called 177Lu-IPN01087)
Intervention description: The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 14.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This study was conducted to advance new treatment for patients with metastatic or locally
      advanced cancers expressing Neurotensin receptor 1 (NTSR1). This study was the first time the
      investigational drug called 177Lu-3BP-227 was administered to patients under controlled
      conditions of a clinical study.

      The purpose of this study was to evaluate how safe the investigational drug is as well to
      verify how well it is tolerated by patients after several intravenous administrations. In
      addition, the effect of the study drug on tumoral lesions and how it distributes throughout
      the body and at which rate it is removed from the body was evaluated. Since 177Lu-3BP-227 is
      a radio-labelled drug, it also measured how the emitted radiation is distributed throughout
      the body (dosimetry).

      The study consisted of a phase I dose escalation part. The study originally planned to
      include a phase II study however due to early termination (not due to safety concerns) the
      study did not progress to phase II and was stopped during phase I. For the phase I dose
      escalation part, it was anticipated that approximately 30 subjects will be included, in up to
      six escalation steps. No expansion cohorts were implemented.
    

Eligibility criteria:

        Inclusion Criteria :

          -  Signed informed consent form prior to all study procedures

          -  Aged 18 years or older.

          -  Histologically or cytologically confirmed unresectable locally advanced or metastatic
             disease and has received prior lines of standard-of-care chemotherapy/treatment and
             has no further suitable treatment options and documented decision by a
             multidisciplinary oncology board including a specialist of the concerned pathology.

          -  Subjects have (a) pancreatic ductal adenocarcinoma (PDAC), or (b) colorectal
             adenocarcinoma (CRC), or (c) gastric adenocarcinoma (GC), or (d) gastrointestinal
             stromal tumours (GIST), or (e) squamous-cell carcinoma of head and neck (SCCHN), or
             (f) Ewing Sarcoma (ES)

          -  Tumour showing: (a) by uptake of 177Lu-3BP-227 (screening formulation) in known
             primary or metastatic sites as judged by the investigator to be greater than
             background; or (b) uptake of 111In 3BP 227 in known primary or metastatic sites (for
             subjects who participated in Study D FR 01087 002) as judged by the investigator to be
             greater than background.

          -  Measurable disease (based on RECIST version1.1).

          -  Documentation of progressive disease in the 6 months prior to study start (treatment).

          -  Eastern Cooperative Oncology Group performance status of 0 or 1 (unless if disability
             is related to surgery in ES and Agreed with the Sponsor).

          -  Adequate organ function as evidenced by: (a) Leukocytes ≥3000/μL (b) Absolute
             neutrophil count ≥1500/µL (c) Platelets ≥75,000/µL (d) Hb >9 g/dL or >10 g/dL (if
             history of cardiac disease) (e) Total serum bilirubin ≤2 times upper normal
             institutional limits (ULN) (f) Aspartate aminotransferase/alanine aminotransferase
             (ALT) ≤2.5×ULN (or ≤5×ULN, if subject has liver metastases) (g) Estimated glomerular
             filtration rate (eGFR) ≥55 mL/min.

          -  Estimated life expectancy >3 months.

          -  Female subjects must not be pregnant or lactating at study entry and during the course
             of the study and must not become pregnant for at least 6 months following the last
             study treatment. Women of childbearing potential must agree to use a highly effective
             method of contraception

          -  For male subjects, must not father children during the study and for at least 6 months
             after the last study treatment and in addition must agree to use a condom for this
             period to protect his partner from contamination with the IMP. For males with partners
             who are of child bearing potential, effective contraception is a combination of male
             condom with either cap, diaphragm or sponge with spermicide (double barrier methods),
             but these are not considered to be highly effective. A man is considered to be
             infertile if he has had bilateral orchidectomy or successful vasectomy. Effective
             contraception includes a female partner of childbearing potential if she is using
             highly efficacious contraception, but the male subject must agree to use a condom to
             protect his partner as described above.

          -  Must be willing and able to comply with study restrictions and to remain at the clinic
             for the required time during the study period and willing to return to the clinic for
             the follow-up evaluation, as specified in the protocol.

        Exclusion Criteria :

          -  Prior treatment received (a) Any antitumor treatment since last documented disease
             progression (b) Any chemotherapy within 3 weeks or nitrosourea within 6 weeks prior to
             first treatment investigational medicinal product (IMP) administration (c) Any
             curative radiotherapy within 4 weeks, or palliative radiotherapy within 7 days prior
             to first treatment IMP administration (d) Any monoclonal antibodies within 4 weeks or
             tyrosine kinases inhibitors within 2 weeks prior to the first treatment IMP
             administration, (e) Any other IMP within 2 weeks prior to first treatment IMP
             administration, if the previous compound is a mechanism-based molecularly targeted
             agent whose half-life (t1/2) is not well-characterized.

          -  Brain metastases.

          -  Nephrectomy, renal transplant or concomitant nephrotoxic therapy putting the subject
             at high risk of renal toxicity during the study.

          -  Only non-measurable metastatic bone lesions

          -  Existing or planned colostomy during study participation.

          -  Any history of inflammatory bowel disease.

          -  Any uncontrolled significant medical, psychiatric or surgical condition or laboratory
             finding, that would pose a risk to subject safety or interfere with study
             participation or interpretation of individual subject results.

          -  Clinically significant abnormalities on electrocardiogram (ECG) at screening including
             corrected QT interval (Fridericia's formula) >450 msec for males or 470 msec for
             females at screening.

          -  Previously received external beam irradiation to a field that includes more than 30%
             of the bone marrow or kidneys.

          -  Any unresolved NCI-CTCAE Grade 2 or higher toxicity (except alopecia) from previous
             antitumor treatment and/or medical/surgical procedures/interventions.

          -  Known allergy to IMP or its excipients administered in this study, including imaging
             contrast media.

          -  Positive pregnancy test (female subjects).

          -  Likely to be uncompliant or uncooperative during the study, in the judgment of the
             investigator.

          -  Unable to understand the nature, scope, and possible consequences of the study, in the
             judgment of the investigator.

          -  Sponsor employees or investigator site personnel directly affiliated with this study,
             and their immediate families. Immediate family is defined as a spouse, parent, child
             or sibling, whether biological or legally adopted.